NCT03552991 is a Phase 4 clinical trial of Agiocur Pregranules in Diabetes Mellitus, Type 2, sponsored by Samsung Medical Center.

Who is sponsoring NCT03552991?

NCT03552991 is sponsored by Samsung Medical Center.

What drugs are being tested in NCT03552991?

Interventions in NCT03552991: Agiocur Pregranules.

What condition does NCT03552991 study?

NCT03552991 studies Diabetes Mellitus, Type 2.

Is NCT03552991 still recruiting?

NCT03552991 is currently completed. Last updated 10 June 2018.

Last reviewed 2018-06-10 · How we verify

NCT03552991

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of Dietary Fiber on Glucose Control in Subjects With Type 2 Diabetes Mellitus

Completed Phase 4 Last updated 10 June 2018

What this trial tests

Phase 4 trial testing Agiocur Pregranules in Diabetes Mellitus, Type 2 in 14 participants. Completed in 31 May 2018.

Timeline

1 February 2014

Primary endpoint
1 October 2015

31 May 2018

Quick facts

Lead sponsor	Samsung Medical Center
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	14
Start date	1 February 2014
Primary completion	1 October 2015
Estimated completion	31 May 2018

Drugs / interventions tested

Agiocur Pregranules — full drug profile →

Conditions studied

Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →

Sponsor

Samsung Medical Center

Who can join

50 and older, any sex, with Diabetes Mellitus, Type 2. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Fasting glucose
Time frame: the 4th week of study
By comparing the level of 4th week, compared to baseline
Glycoalbumin
Time frame: the 4th week of study
By comparing the level of 4th week, compared to baseline
Insulinogenic index
Time frame: the 4th week of study
By comparing the level of 4th week, compared to baseline
Quantitative insulin sensitivity check index (QUICKI)
Time frame: the 4th week of study
By comparing the level of 4th week, compared to baseline. QUICKI is derived from fasting blood glucose and insulin level, reflecting insulin sensitivity.

Sponsor's own description

The purpose of this study is to determine the effect of a commercial dietary fiber supplement on patients with type 2 diabetes mellitus, in the way of glucose control, insulin action in the body, and the gut microbiota (bacteria) abundance.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Modulating the Microbiota as a Therapeutic Intervention for Type 2 Diabetes.
Huda MN, Kim M, Bennett BJ. · · 2021 · cited 89× · PMID 33897618 · DOI 10.3389/fendo.2021.632335

Verify or expand the search:

Other recruiting trials for Diabetes Mellitus, Type 2

Currently open trials in the same condition.

NCT07415954 — A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 · Phase 2 · recruiting
NCT07532863 — A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Part · recruiting
NCT07336329 — Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use · NA · recruiting
NCT07242469 — A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006) · Phase 1 · recruiting
NCT07444203 — Transformative Research in Diabetic Nephropathy 2.0 · recruiting

Other Samsung Medical Center trials

Trials by the same sponsor.

NCT07482865 — Routine Versus Provisional Distal Perfusion Catheter Placement in Patients Undergoing Mechanical Circulatory Support · NA · not yet recruiting
NCT07467213 — Routine Use of Potassium Competitive Acid Blocker vs. Guideline-Directed Gastrointestinal Protection Strategy in Acute M · Phase 4 · not yet recruiting
NCT07530913 — Effectiveness Analysis of a Rehabilitation Exercise Platform for Living Donor Liver Transplantation Patients · NA · enrolling by invitation
NCT07500701 — Salvage Moderate Hypofractionated Versus Ultrahypofractionated Radiotherapy for Biochemical Recurrence After Radical Pro · Phase 3 · recruiting
NCT07409441 — Korea Acute Myocardial Infarction Registry · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03552991 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Samsung Medical Center
Last refreshed: 10 June 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03552991.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing